Key facts
- This page summarizes Barbara K. Finck's Form 4/A - Amendment filing for Comera Life Sciences Holdings, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Feb 2023, 16:34.
Barbara K. Finck - 04 Jan 2023 Form 4/A - Amendment Insider Report for Comera Life Sciences Holdings, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 04 Jan 2023
- Net transaction value
- +$9,999
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 14 Feb 2023, 16:34:50 UTC
- Original report date
- 06 Jan 2023
- Prior SEC filing
- 14 Feb 2023
- Next SEC filing
- 20 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ryan M. Rourke Reed, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Barbara K. Finck filed Form 4/A - Amendment for Comera Life Sciences Holdings, Inc. on 14 Feb 2023.
Change
- Previous filing in this sequence was filed on 14 Feb 2023.
- Current net transaction value: +$9,999.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CMRA
transaction
Common Stock
Purchase
- Transaction value
- $8,310
- Shares
- +6,756
- Change %
- +42%
- Price
- $1.23
- Shares after
- 23,033
- Date
- 04 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CMRA
transaction
Derivative
Warrant (Right to Buy)
Purchase
- Transaction value
- $1,689
- Shares
- +6,756
- Change %
- Price
- $0.2500
- Shares after
- 6,756
- Date
- 04 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,512
- Exercise price
- $1.23
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Barbara K. Finck is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
This Form 4/A is being filed to (i) correct a typographical error in the transaction code disclosed in Column 3 in Table I and Column 4 in Table II in the original Form 4, filed on January 6, 2023, from "A" to "P" and (ii) correct a typographical error in the power-of-attorney of the reporting person.
Footnote F2
The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 6,756 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules.
Footnote F3
The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.
SEC remarks
Exhibit 24 Power of Attorney filed herewith.